Presentation Outline

- Overview
- Anatomy of Head and Neck
- Multiple Primary and Histology Coding Rules Refresher
- Collaborative Stage Data Collection System
- C.S. Site Specific Factors
- Treatment Options
- Documentation
What is head and neck cancer?

- Head and Neck Cancer is a group of cancers that includes tumors in several areas above the collar bone.
Head and Neck: General Facts

- 2009 estimated US 35,720 new cases, ACS
- Men > women
- Age > 45
- 90% of head and neck cancer are Squamous cell ca
- Originate from the mucosal lining (epithelium)
- Spread to Lymph nodes of the neck
- Lymph node of the neck often the first (and sometimes only) sign at diagnosis
- Environmental and lifestyle risk factors
  - Smoking, alcohol, virus (HPV & CMV), Hematopoieic stem cell transplantation (HSCT - Oral SCC)
  - Highly curable if detected early

http://www.cancer.org/Research/CancerFactsFigures/index

### Leading Sites of New Cancer Cases and Deaths - 2011 Estimates*

<table>
<thead>
<tr>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Estimated New Cases</strong></td>
<td><strong>Estimated New Cases</strong></td>
</tr>
<tr>
<td>Prostate</td>
<td>Breast</td>
</tr>
<tr>
<td>240,890 (29%)</td>
<td>230,480 (30%)</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>Lung &amp; bronchus</td>
</tr>
<tr>
<td>115,040 (14%)</td>
<td>106,010 (14%)</td>
</tr>
<tr>
<td>Colon &amp; rectum</td>
<td>Colon &amp; rectum</td>
</tr>
<tr>
<td>71,850 (9%)</td>
<td>69,360 (9%)</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>Uterine corpus</td>
</tr>
<tr>
<td>52,020 (6%)</td>
<td>46,470 (6%)</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>Thyroid</td>
</tr>
<tr>
<td>40,010 (5%)</td>
<td>36,550 (5%)</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>Non-Hodgkin lymphoma</td>
</tr>
<tr>
<td>37,100 (5%)</td>
<td>30,300 (4%)</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>Melanoma of the skin</td>
</tr>
<tr>
<td>30,200 (4%)</td>
<td>30,220 (4%)</td>
</tr>
<tr>
<td>Oral cavity &amp; pharynx</td>
<td>Kidney &amp; renal pelvis</td>
</tr>
<tr>
<td>27,710 (3%)</td>
<td>23,800 (3%)</td>
</tr>
<tr>
<td>Leukemia</td>
<td>Ovary</td>
</tr>
<tr>
<td>25,310 (3%)</td>
<td>21,900 (3%)</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Pancreas</td>
</tr>
<tr>
<td>22,050 (3%)</td>
<td>21,880 (3%)</td>
</tr>
<tr>
<td>All sites</td>
<td>All sites</td>
</tr>
<tr>
<td>822,180 (100%)</td>
<td>774,370 (100%)</td>
</tr>
</tbody>
</table>

*Note: includes basal and squamous cell skin cancers and esophagus cancers except urinary bladder

Leading Sites of New Cancer Cases and Deaths among African Americans

- Prostate
- Lung & bronchus
- Colon & rectum
- Uterine corpus
- Thyroid
- Kidney
- Non-Hodgkin lymphoma
- Oral cavity & pharynx
- Pancreas
- Leukemia
- All sites

©2011, American Cancer Society, Inc., Surveillance Research
Risk Factors

- **Tobacco Products**
  - Smoking Tobacco
  - Cigarettes
  - Cigars
  - Pipes
  - Chewing Tobacco
  - Snuff

- **Ethanol Products**
  - Alcohol
  - Mouthwash containing alcohol

- **Chemicals**
  - Asbestos
  - Chromium
  - Nickel
  - Arsenic
  - Formaldehyde

**Other Factors:**

- Ionizing Radiation
- Plummer-Vinson Syndrome
- Epstein-Barr Virus
- Human Papilloma Virus
- Chronic irritation
- Diet (lack fruits, vegetables)
- Immunosuppressive medication
- Gender

Lifestyle

- Immigrants from Southeast Asia & East Indies:
  - paan (betel quid)
  - Oral cancer lip, mouth, tongue, and pharynx; and esophageal cancer

- South Americans:
  - mate, a tea-like beverage
  - Mouth, throat, esophagus, and larynx cancer

- Poor oral hygiene (ill-fitting bridgework, broken teeth, mucosa irritated by sharp or jagged teeth)

http://www.cancer.gov/cancertopics/factsheet/Sites-Types/head-and-neck

Tobacco Use

SOME OF THE HARMFUL CHEMICALS FOUND IN CIGARETTE SMOKE

- Acetone: Used in nail polish remover and paint stripper
- Butane: Cigarette lighter fluid
- Cadmium: Poisonous chemical that causes liver, kidney, brain damage and is commonly found in car batteries
- Carbon Monoxide: Gas found in car exhaust smoke
- Arsenic: Person used in pest control and insecticide

http://www.myquitsmokingsecrets.com/images/chemical.jpg

H&N Possible Occupational Risks

- Woodworking-
  - Wood dust as a "confirmed" human carcinogen
- Leather manufacturing-Shoe
  - Carcinogens such as polychlorophenols and their sodium salts and chromium (VI) compounds
- Nickel Refining
  These include pulmonary and sino-nasal cancer from exposure to the dusts involved in certain, now obsolete, processes, dermatitis and nickel carbonyl poisoning
- Textile industry—
  - exposed to cotton dust, and in workers involved in spinning or weaving
- Radium dial painting- Medical exposure

Head and Neck Signs & Symptoms

**Signs**
- Red or white patch in the mouth
- Oral ulceration, swelling, or loose tooth
- Lateral neck mass
- Rapidly growing thyroid mass
- Cranial nerve palsy
- Orbital mass
- Unilateral ear effusion, earache

**Symptoms**
- Sore throat
- Hoarseness
- Stridor
- Difficulty in swallowing
- Lump in neck
- Unilateral ear pain
- Many are "silent"
  - No pain or other symptoms until advanced stages

Head and Neck Presentations

- Persistently enlarged neck nodes in younger patients (30-50 years)
- HPV
- Persistent unilateral otalgia with no signs of ear infection in patients over 30
- Recent onset wheeze in a patient over 40, usually a heavy smoker

**Human Papillary Virus (HPV)**

Courtesy of Dr. Steve Debbink
Dental Director, AIDS Resource Ctr of Wisconsin
http://www.hivdent.org/_picturegallery_/HPV1.htm
Human Papillomavirus (HPV)

- **DNA virus**
- Preferentially infect squamous epithelial cells
- >100 genotypes
- >240 genital HPV types
- The most common STD worldwide
- 80% sexually active adults in the US infected with at least one HPV type by age 50
- Peak prevalence during adolescence and young adulthood
- Prevalence declines with age
- HPV 16 is the most common HR type

Cytomegalovirus (CMV)

- Oncovirus
- Most common salivary gland cancers

http://theholisticdentist.files.wordpress.com/2011/06/hpv.jpg

Head & Neck Diagnostic Workup

Physical Exam
- Head and Neck exam
- Mirror and fiberoptic examination as clinically indicated
- Dental Evaluation, including panorex
- HPV testing
- Nutrition, speech & swallowing evaluation/therapy and audiogram as indicated

Panendoscopy
- Examination under anesthesia with endoscopy as indicated
- Preanestensia studies
- Biopsy
  - Brush
  - Excisional

Radiology
- Chest imaging
- Ct with contrast and/or MRI with contrast of primary and neck
- Consider PET-CT for stage III-IV disease

Investigations used for H&N Cancer
- Dental Exam
- Imaging
  - Computed tomography scanning (CT)
  - Positron emission tomography (PET)

Positron emission tomography-computed tomography scans showing: left Neck
http://www.bmj.com/content/341/bmj.c4684
Which Diagnostic Test?

<table>
<thead>
<tr>
<th>CT scan</th>
<th>MRI</th>
<th>PET</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Rapid acquisition time</td>
<td>• Multiple planes</td>
<td>• Entire body</td>
</tr>
<tr>
<td></td>
<td>assess tumor volume</td>
<td>• May delineate questionable</td>
</tr>
<tr>
<td></td>
<td>• Superior soft tissue</td>
<td>findings from other scans</td>
</tr>
<tr>
<td></td>
<td>resolution</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• No IV contrast</td>
<td></td>
</tr>
<tr>
<td>• IV contrast with</td>
<td>• Patient movement</td>
<td>• Cost</td>
</tr>
<tr>
<td>allergy concerns</td>
<td>distorts</td>
<td>• Availability</td>
</tr>
<tr>
<td>• Poor soft tissue</td>
<td>• Bone detail inferior</td>
<td>• Equivocal results may not be</td>
</tr>
<tr>
<td>contrast</td>
<td>• Longer time for patient</td>
<td>helpful</td>
</tr>
<tr>
<td>• Metallic dental</td>
<td>• Any metal may preclude</td>
<td></td>
</tr>
<tr>
<td>appliances interfere</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NCCN Practice Guidelines Narrative Summary
PET and PET/CT

Head and Neck Cancers (v.2.2010)
- Occult primary: PET/CT (before biopsy) (diagnosis).
- Initial staging of cancer of the oral cavity, oropharynx, hypopharynx, glottic larynx, and supraglottic larynx: Consider PET/CT for stage III-IV disease (staging).
- Initial staging of mucosal melanoma: Chest imaging or consider PET scan to rule out metastatic disease.
- Initial staging of cancer of the nasopharynx: Imaging for distant metastases (chest, liver, bone) for WHO class 2-3/Ñ2-3 disease (may include PET scan and/or CT) (staging).
- Post-treatment evaluation of cancers of the head and neck (minimum 12 weeks): PET/CT (suggest full dose CT with IV contrast). If PET/CT is performed and negative for suspicion of persistent cancer, further cross-sectional imaging is optional (restaging).

http://www.snm.org/docs/PET_PROS/NCCNPracticeGuidelinesII.pdf
ICD-O Topography Codes (Anatomic Site)

<table>
<thead>
<tr>
<th>Site Group</th>
<th>ICD-O-3 Site</th>
<th>ICD-O-3 Histology (Type)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Cavity and Pharynx</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lip</td>
<td>C000-C009</td>
<td>excluding 9050-9055, 9140, 9690.9992</td>
</tr>
<tr>
<td>Tongue</td>
<td>C019-C029</td>
<td></td>
</tr>
<tr>
<td>Salivary Gland</td>
<td>C079-C089</td>
<td></td>
</tr>
<tr>
<td>Floor of Mouth</td>
<td>C040-C049</td>
<td></td>
</tr>
<tr>
<td>Gum and Other Mouth</td>
<td>C030-C039, C050-C059, C060-C069</td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>C110-C119</td>
<td></td>
</tr>
<tr>
<td>Tonsil</td>
<td>C090-C099</td>
<td></td>
</tr>
<tr>
<td>Oropharynx</td>
<td>C100-C109</td>
<td></td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>C129, C130-C139</td>
<td></td>
</tr>
<tr>
<td>Other Oral Cavity and Pharynx</td>
<td>C140, C142-C148</td>
<td></td>
</tr>
</tbody>
</table>

Head and Neck Site Group

- Oral Cavity
- Lip and oral cavity (C00-C05.0)
  - Lip
  - Tongue
  - Gum and other mouth
  - Mouth Subsites
  - Salivary Glands (C07)
  - Tonsil
- Pharynx
  - Oropharynx (C05.1, C05.2, C10)
  - Nasopharynx (C11)
  - Hypopharynx C12.9, C13)
  - Other Pharynx
Head & Neck Histologic Type

- Depends on the location in the oral cavity and neck
- Squamous cell carcinoma
  - Most common: 90% Squamous cell ca of the oral cavity and oropharynx
    - more aggressive depending on the location of the tumor
    - Stage is critical factor for prognosis
- Melanoma mucosal 15-20%
- KS oral mucosa on the palate, gingiva and tongue
- Hodgkin Lymphoma, extranodal, rare, Walderyer ring, palatine tonsil
- Extramedullar myeloid sarcoma, gingiva, 3.5%

Reference: WHO, Pathology & Genetics, H&N Tumors, Tumor of oral cavity, 2005

Distribution by Site:
Squamous Cell Carcinoma

<table>
<thead>
<tr>
<th>General Location</th>
<th>Specific Location</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tongue</td>
<td>Lateral surface</td>
<td>26%</td>
</tr>
<tr>
<td></td>
<td>Ventral surface</td>
<td></td>
</tr>
<tr>
<td>Oral Pharynx</td>
<td>Soft palate</td>
<td>23%</td>
</tr>
<tr>
<td></td>
<td>Tonsillar pillars</td>
<td></td>
</tr>
<tr>
<td>Lip</td>
<td>Vermilion surface</td>
<td>20%</td>
</tr>
<tr>
<td>Floor of Mouth</td>
<td>Floor of mouth</td>
<td>17%</td>
</tr>
<tr>
<td>Gingiva</td>
<td>Gingiva</td>
<td>9%</td>
</tr>
<tr>
<td>Buccal Mucosa</td>
<td>Buccal mucosa</td>
<td>3%</td>
</tr>
<tr>
<td>Hard Palate</td>
<td>Hard palate</td>
<td>2%</td>
</tr>
</tbody>
</table>

Reference: www.usc.edu/hsc/dental/opath/Chapters/Chapter13_Text.html
Head & Neck Histologic Type

- **Basaloid squamous cell carcinoma**, Rare
- **Keratinizing squamous cell carcinoma**
  - Nasopharynx
  - Also called WHO type 1
  - Minority of tumors
  - Often EBV-, older age group
- **Nonkeratinizing carcinoma-differentiated**
  - Nasopharynx
  - Also called WHO type 2
  - Rare in childhood

Reference: WHO, Pathology & Genetics, H&N Tumors, Tumor of oral cavity, 2005

---

Head & Neck Histologic Type

- **Nonkeratinizing carcinoma-undifferentiated**
  - Nasopharynx
  - Also called WHO type 3
  - Very rare in US, common in Taiwan and China (EBV endemic area)
- **Papillary squamous cell carcinoma**
  - Rare; precursor lesion unknown
- **Spindle cell carcinoma**
  - Also called sarcomatoid carcinoma or carcinosarcoma
  - Uncommon in larynx; more common elsewhere in upper aerodigestive tract
- **Verrucous carcinoma**
  - Also called Ackerman’s tumor
  - Occurs anywhere in upper aerodigestive tract

Reference: WHO, Pathology & Genetics, H&N Tumors, Tumor of oral cavity, 2005
Oral Cavity

- Histology
- Squamous cell Carcinoma
  - Includes inner lip, tongue, floor of mouth, gingivae, hard palate
  - Associated with tobacco use, especially chewing tobacco or "dip"; Heavy alcohol use

Lip (C00.0-C00.9)

- Parts: skin, vermilion border, mucosa, frenulum lip, commissure
  - Lower lip has better prognosis
  - C00.0, .1, .2 external
  - C00.3, .4, .5 mucosa
  - C00.6 commissure
  - C00.8 overlapping

Lip

- 23% of oral cancer incidence
  - Lower lip > 90%
  - Upper lip 2-8%
  - Commissure 1-2%
- Most common oral cancer (42-45% of cases)
- Rest basal cell, salivary gland, melanoma
- 90% occur on lower lip, usually along vermillion border
- Symptoms: sore that won't heal, lump in lip
- **Risk factors:** chronic sunlight, pipe smoking, cigarette smoking, poor oral hygiene, fair complexion, organ transplant recipients
- Low risk of metastatic extranodal spread; early to adjacent skin, orbicular muscle; late to buccal mucosa, mandible, mental nerve

Question
Reportability/Primary Site—Head & Neck:
If a wedge resection/shield resection is performed on the lower lip for SCCA and the path report refers to "lip, NOS" with no mention of vermillion border, is this case reportable?

Answer
Review the operative and pathology reports, and the physical exam for mention of "mucosal surface" (reportable) or "skin" (not reportable).
If neither are mentioned, lip, NOS is reportable per the ICD-O-3 code of C009.

Question: 20051049

NR to FCDS
Tongue (C01.9 – C02.9)

- 28% oral cancer incidence (2007 ACS)
- Est. 7,320 cases USA 2004 (0.3%)
  - China 34,954; India 28,662
- Parts: Tip, anterior 2/3 tongue, ventral & dorsal surface, frenulum linguae
- Symptoms and Diagnosis: Leukoplakia
- Histology: Squamous cell 90%
- Usually lateral aspect of middle third of tongue
- More likely to metastasize than other intraoral carcinomas (70% have metastases at presentation)
- Spread eventually to floor of mouth and root of tongue
- Metastases: ipsilateral subdigastric, submandibular, midjugular nodes; may spread directly to lower jugular nodes
- Poor prognostic factors: involvement of posterior third of tongue

http://www.advancedonc.com/tongue.htm

Anatomy around the Tongue

http://www.histology.leeds.ac.uk/oral/tongue.php
Squamous cell CA Tongue

http://www.gastrohep.com/images/image.asp?id=646

Gum (C03.0-C03.9)

- Parts: gingiva, alveolar ridge, periodontal
  - C03.0 upper
  - C03.1 lower
  - C03.9 NOS
- Snuff users 50 x risk (92% users male)
  - 2-3 times level of nicotine
Floor of Mouth (C04.0-C04.9)

- 16% of all oral cancers
- Symptoms
  - Lesion
  - Decreased tongue mobility
- < 50% local at diagnosis

http://www.histology.leeds.ac.uk/oral/mouth.php

Hard Palate (C05.0, C05.8, C05.9)

- Parts: Roof of mouth (NOT soft palate or uvula)
- Histology (74% malignant, 26% benign)
  - Squamous cell 53%
  - Adenocarcinoma 4%
  - Adenoid cystic 15%
  - Anaplastic CA 4%
  - Mucoepidermoid 10%
  - Other 14%
- Reverse smoking
- 70% tumors extend beyond hard palate

http://www.cdc.gov/cancer/npcr/training/nets/module5/
Cheek/Buccal Mucosa (C06.x)

- Parts: Cheek, vestibule, alveolar sulcus, retromolar trigone, minor salivary glands NOS
- Page 33 ICD-O-3: Minor salivary gland tumors can be found anywhere in oral cavity & surrounding organs – code to specific site if noted, else code to C06.9 (NOS)

http://www.cdc.gov/cancer/npcr/training/nets/module5/

Soft Palate

- **Squamous cell carcinoma-palate**
- 5-6% of intraoral squamous cell carcinoma
- Most common malignancy of palate
- Usually soft palate, 60% male
- Usually involves adjacent tissues at diagnosis (hard palate tumors involve underlying bone)
- 1/3 have metastases to internal jugular, submandibular and retropharyngeal nodes at diagnosis; rarely bilateral
- Pathology report should describe involvement of underlying bone
3 Subsites of Pharynx

- **Nasopharynx** (upper part of the pharynx, behind the nose)

- **Oropharynx** (middle part of the pharynx, soft palate the back of the mouth, base of the tongue, and the tonsils)

- **Hypopharynx** (lower part of the pharynx posterior pharyngeal wall, cricoid)


Nasopharynx (C11.0-C11.9)

- Swollen or tender lymph nodes
- Difficulty trouble opening the mouth, chewing and swallowing
- Ear infections
- Nasal obstruction or bleeding
- Noticeable nasal "twang" in the voice
- Epstein Barr Virus
- Nonkeratinizing SCC 50+%  
- Keratinizing SCC 30%
- Lymphoepithelioma 25% (a variant of SCC)
Nasopharynx

- Arises in the nasopharynx (region of nasal cavities)
- Eustachian tubes connect with the upper part of the throat
- Common to the HNSCC

Parts of Oropharynx

(C01.9, C05.1, C05.2, C09.x, C10.x)

- Subsites of Oropharynx
  - C01.9 Base of tongue
  - C05.1 Soft palate
  - C05.2 Uvula
  - C09.1 Tonsillar fossa
  - C09.2 Tonsillar pillar
  - C09.9 Tonsil, NOS
  - C10.0 Vallecula
  - C10.2 Lateral wall
  - C10.3 Posterior wall
  - C10.9 Oropharynx, NOS
  - NOTE C10.1 Anterior surface epiglottis

© 2004 A.D.A.M., Inc.
Oropharynx (C10.0-C10.9)

- Originate in the oropharynx, middle part of the throat that includes the soft palate, base of tongue, and tonsils
- Squamous cell carcinoma of the tonsils - HPV


Oropharynx

**Symptoms**
- Persistent sore throat or cough
- Hard or painful swallowing
- Unexpected weight loss
- Vocal changes
- Ear pain
- A lump in the throat, mouth or neck
- Dull chest pain

**Risk Factors**
- Smoking and chewing tobacco
- Heavy alcohol use
- Diet low in fruits and vegetables.
- Human papilloma virus (HPV) infection
Hypopharynx (C12.9, C13.0-C13.9)

- Tumor in the pyriform sinuses (70%), posterior pharyngeal wall, and postcricoid area (15%).
- Usually frequent Dx with advanced stage at Dx
- Metastasize early due to extensive lymphatic network around the larynx


Parts of Hypopharynx (C12.9, C13.x)

- C12.9 Pyriform sinus (most common, most lethal)
- C13.0 Postcricoid
- C13.1 Hypo-pharyngeal aspect of aryepiglottic fold
- C13.2 Posterior wall
- C15.0 Esophagus
Salivary Glands (C07.9-C08.9)

The Major Salivary Glands
- Parotid: serous, most common
- Submandibular: mucous & serous
- Sublingual tumors are rare and may be difficult to distinguish from minor salivary gland primary tumors of anterior floor of mouth

The Minor Salivary Glands

Symptoms
- Swelling under the chin or jawbone
- Numbness or paralysis in facial muscles
- Persistent face, chin or neck pain

Regional lymph nodes: nodal metastases usually evident on initial clinical evaluation; low grade tumors rarely metastasize to regional nodes, high grade tumors often do; nodal involvement tends to be orderly from intraglandular to adjacent nodes to upper and midjugular nodes, and occasionally to retropharyngeal nodes; bilateral nodal involvement is rare

Metastases: usually to lungs

Risk Factors
- Smoking and chewing tobacco
- Heavy alcohol use

Salivary Gland Histologic Type

- Acinic cell 1-3% of salivary gland tumors #2 childhood salivary gland malignancy after mucoepidermoid carcinoma
- Adenocarcinoma Usually not in glottis May arise from surface epithelium
- Adenoid Cystic: Most common in submandibular, sublingual or minor salivary glands
- Malignant mixed
- Mucoepidermoid Most common 2/3 occur in parotid gland & palate
- Squamous Cell
- Schwannoma
  - May arise from facial nerve and present as salivary gland tumor
  - Gross: encapsulated
- Basal cell adenocarcinoma also called basaloid carcinoma
- 1-2% of salivary gland carcinomas
- Cystadenocarcinoma
- Papillary adenocarcinoma <3% of parotid tumors

Children: pleomorphic adenoma most common, but more often malignant; most common malignant tumors are mucoepidermoid carcinoma, adenoid cystic carcinoma, acinic cell carcinoma

http://www.histology.leeds.ac.uk/oral/salivary.php
Parotid Gland Anatomy (C07.9)

- Largest salivary gland
- Lies between the mandible and sternomastoid and over both
- Lymphatics: Paraparotid & Intraparotid nodes & Superficial & Deep Cervical nodes

Signs & Symptoms

- Facial nerve paralysis
- Pain or facial paresis

Parotid Gland – Histologic Type

- Mucoepidermoid carcinoma 30%
  - 2/3 occur in parotid gland
  - Wide age range, mean 49 years, range 15-86 years, no gender predominance
  - Low grade: 15% recur, 5 year survival 90-98%; usually stage I
  - High grade: 25% recur, 5 year survival 50-56%; deaths usually within first 5 years

- Adenocarcinoma
- Malignant pleomorphic adenoma, rare
- Adenoid cystic carcinoma
- Sebaceous carcinoma, rare
- Papillary adenocarcinoma <3% of parotid tumors
- Salivary duct carcinoma
- Carcinosarcoma
- Squamous cell carcinoma, rare
  - Most tumors of parotid gland are metastases to intraparotid lymph nodes from primaries in oral cavity, upper aerodigestive tract or skin
  - May represent malignant component of malignant mixed tumor or high grade mucoepidermoid carcinoma
  - Rapid growth with infiltration of surrounding structures, regardless of origin

http://emedicine.medscape.com/article/1289616-overview#aw2aab6b4
Submandibular Gland: Anatomy

- Large superficial lobe, small deep lobe, size of walnuts (10g.)
- Connect around the mylohyoid
- Superficial lobes lies at the angle of the jaw

Sublingual Gland: Anatomy (C08.1)

- Smallest of the major salivary glands, almond shape
- Lies just deep to the floor of mouth mucosa, between the mandible & Genioglossus muscle
- No capsule
- Ducts of Rivinus +/- Bartholin’s duct
- Sialogram not possible
- Bounded inferiorly by the mylohyoid muscle
- Artery/Vein: Sublingual branch of Lingual & Submental branch of Facial
- Lymphatics: Submandibular nodes
Minor Salivary Glands: Anatomy

- Unlike the major salivary gland, 500-1,000 approx
- Each salivary unit has its own simple ducts
- Salivary glands in Buccal, Labial, Palatal, Lingual regions
- Tumor sites: Palate, upper lip, cheek

Lymph Nodes

- Head and Neck cancer often spreads to lymph node rich regions in the head, neck, and face
Head and Neck Lymph Nodes Exam

- **Ant Cervical** Throat, tonsils, post pharynx, thyroid
- **Post Cervical** Back of skull
- **Tonsillar** Tonsils, posterior pharynx
- **Sub-Mandibular** - Floor of mouth
- **Sub-Mental** - Teeth
- **Supra-Clavicular** - Thorax
- **Pre-Auricular** - Ear

Lymph Node Level of Head and Neck

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Submental, submandibular</td>
</tr>
<tr>
<td>II</td>
<td>Upper deep cervical</td>
</tr>
<tr>
<td>III</td>
<td>Middle deep cervical</td>
</tr>
<tr>
<td>IV</td>
<td>Lower deep cervical</td>
</tr>
<tr>
<td>V</td>
<td>Posterior triangle</td>
</tr>
<tr>
<td>VI</td>
<td>Anterior compartment</td>
</tr>
<tr>
<td>VII</td>
<td>Superior mediastinal</td>
</tr>
</tbody>
</table>

NOTE: See further information on lymph node levels below.


Figure 1-2-1. Lymph Node Levels of Head and Neck
Head and Neck Regional Nodes I

1. Submental
2. Submandibular
3. Jugular (deep cervical)
4. Superficial cervical
5. Supraclavicular
6. Prelaryngeal* and paratracheal*
7. Retropharyngeal
8. Parotid
9. Buccal
10. Retroauricular and occipital

* not shown

Head and Neck Regional Nodes II

1 Submental
2 Submandibular
3 Upper jugular
4 Lower jugular
5 Pretracheal
6 Paratracheal
7 Prelaryngeal

Not shown:
Parapharyngeal
Retropharyngeal

Adapted from MedClip,
Grant's Atlas Images 4: Head,
Neck and Cranial Nerves,
Relationship Primary to Nodes

<table>
<thead>
<tr>
<th>Lymphatic drainage</th>
<th>Likely primary sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level I: Includes Submental/Submandibular Submental</td>
<td>Lower lip, chin, anterior oral cavity (including anterior one-third of the tongue and floor of the mouth)</td>
</tr>
<tr>
<td>Level I: Submandibular</td>
<td>Upper and lower lips, oral tongue, floor of mouth, facial skin, Maxillary sinus, nasal cavity, oral cavity, submandibular gland</td>
</tr>
<tr>
<td>Level II: Includes the superior jugular chain nodes extending from the mandible down to the carotid bifurcation and posterior border of the sternocleidomastoid muscle</td>
<td>Oral cavity and pharynx (including soft palate, base of tongue, and pyriform sinus) Nasal cavity, parotid gland</td>
</tr>
<tr>
<td>Level III: Consists of the jugular nodes from the carotid bulb inferiorto the omohyoid muscle</td>
<td>Oral cavity, pharynx, hypopharynx, larynx, and thyroid</td>
</tr>
<tr>
<td>Level IV: Continues from the omohyoid muscle inferiorly to the clavicle</td>
<td>Larynx, hypopharynx, thyroid, cervical esophagus, and trachea</td>
</tr>
<tr>
<td>Level V: Represents the posterior border of the sternocleidomastoid anteriorly, the anterior border of the trapezius posteriorly, and the clavicle inferiorly</td>
<td>Nasopharynx, oropharynx</td>
</tr>
</tbody>
</table>

http://www.cancernetwork.com/cancer-management/head-and-neck/article/10165/1802498

Lymph Node Mets at Diagnosis

- Pyriform sinus – 70%
- Posterior area – 40%
- Posterior hypopharynx – 50%
- Nasopharynx – 75%
- Tonsil – 70%
- Base of tongue – 70%
- Soft palate – 30-65%
- Pharyngeal wall – 30-65%
- Paranasal sinuses – 20%
- Medullary ca of thyroid – 50%
Definitions of Levels for H & N Sites

The definitions of the levels and the lymph node chains included in each level are as follows:

**Level I** (First digit of SSF 3) contains the submental and submandibular triangles bounded by the anterior and posterior bellies of the digastric muscle, and the hyoid bone inferiormost, and the body of the mandible superiorly. Lymph node chains at this level:
- Submandibular
- Submaxillary
- Submental

**Level II** (Middle digit of SSF 3) contains the upper jugular lymph nodes and extends from the level of the skull base superiorly to the hyoid bone inferiormost. Lymph node chains at this level:
- Jugulodigastric
- Subdigastric
- Upper deep cervical
- Upper jugular

**Level III** (Last digit of SSF 3) contains the middle jugular lymph nodes from the hyoid bone superiorly to the level of the lower border of the cricoid cartilage inferiormost. Lymph node chains at this level:
- Middle deep cervical
- Mid-jugular

**Level IV** (First digit of SSF 4) contains the lower jugular lymph nodes from the level of the cricoid cartilage superiorly to the clavicle inferiormost. Lymph node chains at this level:
- Jugulo-omohyoid
  - Supraomohyoid
- Lower deep cervical
- Lower jugular

**Level V** (Middle digit of SSF 4) contains the lymph nodes in the posterior triangle bounded by the anterior border of the trapezius muscle posteriorly, the posterior border of the sternocleidomastoid muscle anteriorly, and the clavicle inferiormost. For descriptive purposes, Level V may be further subdivided into:

SuprACLavicular
- Retropharyngeal
- Parotid
- Buccal
- Jugulodigastric
- Submandibular
- Submental
- Infrahyoid
- Prelaryngeal
- Jugulo-omohyoid
- SuprACLavicular

Metastasis Site of H&N

- Lymph nodes in the upper part of the neck (Occult Primary)
- Patients with cervical lymph node metastases histologically related to a previously treated primary tumor and patients with lymphomas and adenocarcinoma are excluded
- Most epidermoid carcinomas metastatic to lymph nodes of the upper half of the neck will originate from a head and neck primary site
- Squamous carcinomas metastatic to the lower neck may represent a primary site in the head and neck, esophagus, lung, or genitourinary tract
- Check Metastatic disease Lung, Liver, or bone


Multiple Primary Rules
Histology Coding Rules
**MPH – Priority order**

**Documenting the Primary Site**

**Priority of order**

1. Tumor board determination (specialty; general)
2. Staging physician’s site assignment (staging form; TNM statement in record)
3. Total resection of primary tumor (physician’s statement; final diagnosis from pathology report)
4. No resection—use documentation from
   - Endoscopy; Radiation oncologist; Diagnosing MD; Primary care MD; Other MD; Radiologist-imaging; MD-PE

**Equivalent Terms**

(for MP/H rules ONLY)

- Tumor = Mass = Lesion = Neoplasm
- In situ = noninvasive = intraepithelial
- Continuous = contiguous
- Squamous cell carcinoma = squamous cell epithelioma = epidermoid carcinoma
- Type = Subtype = Predominantly = With features of = Major = With ______ differentiation

**MP/H Rules: Single Primary**

- **M1** Unsure Multiple vs Single Tumor – Unknown number
  - When it is not possible to determine if there is a single tumor or multiple tumors, opt for a single tumor and abstract as a single primary. Prepare as one abstract.
    - Tumor not described as metastasis

- **M2** Single Tumor - One tumor
  - A single tumor is always a single primary.
    - Might be overlapping
    - Tumor not described as metastasis
    - Combination of in situ and invasive
MP/H Rules: Multiple Primaries

- **M3** Paired sites – Tumors on **right** and **left** sides are **multiple** primaries (Table 1)

- **M4** Lip – Tumors on **UPPER lip** and **LOWER lip** are **multiple** primaries (C00.x)

- **M5** Gum – Tumors on **UPPER gum** and **LOWER gum** are **multiple** primaries (C03.x)

- **M6** – Tumors in **nasal cavity** and **middle ear** are **multiple** primaries (C30.x)

### Column 1: Paired Sites

<table>
<thead>
<tr>
<th>Column 1: Paired Sites</th>
<th>Column 2: Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parotid Glands</td>
<td>C079</td>
</tr>
<tr>
<td>Major Salivary Glands</td>
<td>C080, C081</td>
</tr>
<tr>
<td>Tonsils</td>
<td>C090, C091, C098, C099</td>
</tr>
<tr>
<td>Nasal Cavity</td>
<td>C300</td>
</tr>
<tr>
<td>Accessory Sinuses</td>
<td>C310, C312</td>
</tr>
<tr>
<td>Middle Ear</td>
<td>C301</td>
</tr>
</tbody>
</table>

MP/H Rules: Multiple Primaries

- **M7** – Tumors with ICD-O-3 topography codes different at 2\textsuperscript{nd} (C\textsuperscript{xxx}) or 3\textsuperscript{rd} (C\textsuperscript{xxx}) character are **multiple** primaries

  **Example**
  - C02.1 Tip of tongue
  - C10.0 Vallecula

- **M8** - An **invasive** tumor following an **in situ** tumor more than **60 days** after diagnosis is a **multiple** primary

- **M9** - Tumors diagnosed more than **five (5) years apart** are **multiple** primaries
MP/H Rules: Multiple Primaries

- **M10** – when histology notes **generic** description WITH more **specific** description it is **SINGLE** primary
  - Cancer/malignant neoplasm, NOS (8000) and another is a specific histology or
  - Carcinoma, *NOS* (8010) *and* another is a specific carcinoma or
  - Adenocarcinoma, *NOS* (8140) *and* another is a specific adenocarcinoma or
  - Squamous cell carcinoma, *NOS* (8070) *and* another is specific squamous cell carcinoma or
  - Melanoma, *NOS* (8720) *and* another is a specific melanoma
  - Sarcoma, *NOS* (8800) *and* another is a specific sarcoma

- **M11** - Tumors with ICD-O-3 histology codes that are different at the first (xxx), second (xxx) or third (xxx) number are **multiple** primaries.

- **M12** - Tumors that **do not meet** any of the above criteria are abstracted as a single primary.
  - *Note 1*: When an invasive tumor follows an in situ tumor **within 60 days**, abstract as a single primary.
  - *Note 2*: All cases covered by Rule M12 have the **same first 3 numbers** in ICD-O-3 histology code.
    - Sample: Multifocal tumors in floor of mouth
    - Sample: In situ following invasive > 60 days apart
Case Scenario: Multiple Primaries

87-year-old female
Tumor on tongue and right floor mouth (extends onto anterior tonsillar pillar)
Needs commando procedure

MPH: Histology

Reminder
Read general rules AND site-specific rules
Look for equivalent terms
Most representative specimen
MP/H Rules: Histology Single Tumor

H1 **No** path/cytology done or **available**?
- Priority
  - Documentation that refers to path
  - Physician’s reference to type of cancer
  - CT, PET or MRI
- Code specific term when documented
- Code 8000 or 8010 as stated by physician

H2 **No** path/cytology of **primary** site
- Code info from metastatic site
- Behavior code /3 at primary site

H3 **One** histologic **type**? — code that
- Do NOT code terms that are not there
- EX: Squamous cell carcinoma = 8070 (NOT nonkeratinizing 8072)
- Do not code 8072 (squamous cell carcinoma non-keratinizing) unless the words “non-keratinizing” actually appear in the diagnosis.

H4 **Invasive AND in situ** = invasive only

H5 Code the most **specific** histologic term using Chart 1 when there are multiple histologies within the same branch
- Use Chart 1
- Cancer/malignant neoplasm, NOS (8000) and a more specific histology or
- Carcinoma, NOS (8010) and a more specific carcinoma or
- Squamous cell carcinoma, NOS (8070) and a more specific squamous carcinoma or
- Adenocarcinoma, NOS(8140) and a more specific adenocarcinoma or
- Melanoma, NOS (8720) and a more specific melanoma or
- Sarcoma, NOS (8800) and a more specific sarcoma

H6 Code to the **highest** number ICD-O-3 code
Paired Sites (Chart 1) and Other Multiple Primaries

Head and Neck Equivalent Terms, Definitions, Charts, Tables and Illustrations C000-C148, C300-C329

Table 1 – Paired Sites

<table>
<thead>
<tr>
<th>Column 1</th>
<th>Column 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paired Sites</td>
<td>Code</td>
</tr>
<tr>
<td>Parotid Glands</td>
<td>C029</td>
</tr>
<tr>
<td>Major Salivary Glands</td>
<td>C030, C031</td>
</tr>
<tr>
<td>Tonsils</td>
<td>C090, C091, C098, C099</td>
</tr>
<tr>
<td>Nasal Cavity</td>
<td>C100</td>
</tr>
<tr>
<td>Accessory Sinuses</td>
<td>C110, C112</td>
</tr>
<tr>
<td>Middle Ear</td>
<td>C101</td>
</tr>
</tbody>
</table>

Table 2 – Changes to Previous SEER Site Grouping Table

<table>
<thead>
<tr>
<th>Code</th>
<th>Site Groupings</th>
</tr>
</thead>
<tbody>
<tr>
<td>C01</td>
<td>Base of tongue</td>
</tr>
<tr>
<td>C02</td>
<td>Other and unspecified parts of tongue</td>
</tr>
<tr>
<td>C05</td>
<td>Palate</td>
</tr>
<tr>
<td>C06</td>
<td>Other and unspecified parts of mouth</td>
</tr>
<tr>
<td>C07</td>
<td>Parotid gland</td>
</tr>
<tr>
<td>C08</td>
<td>Other and unspecified major salivary glands</td>
</tr>
<tr>
<td>C09</td>
<td>Tonsils</td>
</tr>
<tr>
<td>C10</td>
<td>Oropharynx</td>
</tr>
<tr>
<td>C12</td>
<td>Pyriform sinus</td>
</tr>
<tr>
<td>C13</td>
<td>Hypopharynx</td>
</tr>
<tr>
<td>C26</td>
<td>Nasal cavity and middle ear</td>
</tr>
<tr>
<td>C31</td>
<td>Accessory sinuses</td>
</tr>
</tbody>
</table>

Head and Neck Histology Rules (Chart 1)
MP/H Rules: Histology Single Tumor

Chart 1

- **Cancer, Carcinoma NOS** (8000, 8001, 8010)
- **Undifferentiated carcinoma** (8020)
  - **Squamous carcinoma** (8070)
  - **Adenosquamous** (8560)
  - **Adenocarcinoma, NOS** (8140)
  - **8050 – 8052 Papillary, verrucous**
  - **807x variety of SCC**
  - **8082 – 8084 Lymphoepithelial Other SCC**
  - 4 different subgroups

**Code Most Specific Term**

- **Most specific code is toward bottom of chart**
- **Example 1**
  - Buccal cytology: carcinoma, NOS
  - Excision: squamous cell cancer
  - Use code 8070
- **Example 2**
  - Biopsy: squamous carcinoma
  - Resection: spindle cell squamous cell carcinoma
  - Use code 8074
Definition – Most Invasive Tumor

- Definition: tumor with greatest continuous extension
  - Invasive > in situ
  - If all are invasive, highest stage

- Layers of squamous tissue (least to most invasive)
  - Epithelium (in situ)
  - Lamina propria*
  - Submucosa*
  - Muscularis propria*
  *except gum and hard palate

http://www.geocities.com/romaniandentistry/images/pacienti/mucosa.gif

MPH Rules: Histology

Multiple Tumors/Single Tumor

H7 – same as H1 (no path available)
Code the histology documented by the physician when there is no pathology/cytology specimen or the pathology/cytology report is not available.

H8 – same as H2 (code from mets tissue)
Code the histology from the metastatic site when there is no pathology/cytology specimen from the primary site.

H9 – same as H3 (code one if only one listed)
Code the histology when only one histologic type is identified.

H10 – same as H4 (code invasive when in situ + invasive)
Code the histology of the most invasive tumor.

H11 – same as H5 (use Chart 1)
Code the most specific histologic term using Chart 1 when there are multiple histologies within the same branch.

H12 – same as H6 (none of the above)
Code the histology with the numerically higher ICD-O-3 code.
Abstracting Issues

Determine the correct primary site
Overlapping Lesions
Unknown Site with positive lymph node
Many staging schemas

ICD-O-3 – C14.8

- What is the primary site?
  **Very Important to determine the correct primary site**
- Overlapping Lesions
- DO NOT USE C76.0

When the point of origin cannot be determined, use a topography for overlapping sites:
- C02.8 Overlapping lesion of tongue
- C08.8 Overlapping lesion of major salivary glands
- C14.8 Overlapping lesion of lip, oral cavity, and pharynx
H&N SEER Inquiry

**Question** 20110089
Primary site--Head & Neck: What is the correct topography code for squamous cell carcinoma diagnosed from lymph node and deemed to be a head and neck primary but specific site could not be identified? Code C148 or C760?

**Discussion**
**Code C148** is based on note in ICD-O-3 indicating it should be used when a code between C000 and C142 cannot be assigned. Previous SINQ and I&R answers indicated it should be coded to C760.

**Answer**
Assign code C148

Last Updated
08/08/11


---

Unknown Site & Positive Lymph node

What to do when H&N site is unknown and there is a
Supraclavicular lymph node positive
Or
Infraclavicular

It can be from any site in the head and neck
Should be coded to H & N if site is unknown use C14.8


CSv2 Coding Instructions, CSv02.03.02

Schema Selection
http://www.cancerstaging.org/cstage/index.html

- Look for Schema Site
- Click on Site Specific Schema tab on the left
- Select the H&N Schema
- All Florida Cases are coded in CSv02.03.02
# Head and Neck – CS

## CS Fields
- Tumor Size — standard
- Extension
- TS/Ext Eval — standard
- Lymph Nodes
- LN Eval — standard
- LN Pos — standard
- LN Exam — standard
- Mets at Dx
- Mets Eval — standard

(Refer to the CS Extension table for instructions on coding extension.)

## CS Tumor Size

- Lip
  - Upper
  - Lower
  - Other

- Other Mouth
  - Buccal Mucosa
  - Salivary Glands
    - Parotid
    - Submandibular
    - Other Salivary

- Tongue
  - Base
  - Anterior

- Pharynx
  - Oropharynx
  - Anterior

- Gum
  - Upper
  - Lower
  - Other

- Epiglottis
  - Nasopharynx
  - Hypopharynx
  - Other Pharynx

- Floor of Mouth
  - Palate
    - Hard
    - Soft

Code the specific tumor size as stated in the medical record. Use code 992 or 994 if the physician’s statement about T value is the ONLY information available about the size of the tumor.

## Head and Neck – CS Extension & Eval

### General format
- 000 In situ
- 100 Lamina propria/submucosa
- 300 Localized, NOS
- 400-590 Adjacent structures (T3)
- 600-690 Mixed T3-T4 (site specific)
- 700-800 Adjacent structures (T4)
- 950 No evidence of primary tumor (T0)

### CS Eval
- General structure
- 0 clinical only
- 1 invasive techniques, no bx; or needle bx
  - does not meet criteria for pathologic T or N
- 2 autopsy (known or suspected dx)
- 3 pathology
- 5 pre-op tx, clinical eval
- 6 pre-op tx, path eval
- 8 autopsy (dx not suspected)
- 9 unknown, not assessed
SITE SPECIFIC FACTORS - SSF’s

Head and Neck – Carcinoma and melanoma
Lymph nodes
  • Lymph Nodes Levels
  • Upper/Lower Cervical
  • Extracapsular Extension
HPV status
Thickness/depth
Schema discriminator

SSF’s Head and Neck Sites

• SSF1 Size of Lymph Nodes – FCDS Required
  * Except Schema Pharynx other
• SSF2 OBSOLETE - Extracapsular Extension, Lymph Nodes
• SSF3 Levels I-III, Lymph Nodes
• SSF4 Levels IV-V and Retropharyngeal Lymph Nodes
• SSF5 Levels VI-VII and Facial Lymph Nodes
• SSF6 Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes
• SSF7 Upper and Lower Cervical Node Levels
• SSF8 Extracapsular Extension Clinically, Lymph Nodes
• SSF9 Extracapsular Extension Pathologically, Lymph Nodes
• SSF10 HPV (Human Papilloma Virus) Status
• SSF11 Measured Thickness (Depth)
### SSF’s Head and Neck Sites

<table>
<thead>
<tr>
<th>Schema Number</th>
<th>Schema Name</th>
<th>TNM/SS Required</th>
<th>FCDS Required</th>
<th>CoC Additional Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>Buccal Mucosa</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9, 11</td>
</tr>
<tr>
<td>12</td>
<td>Epiglottis Anterior</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 9</td>
</tr>
<tr>
<td>17</td>
<td>Base of Tongue</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9, 11</td>
</tr>
<tr>
<td>15</td>
<td>Great Oropharynx</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9</td>
</tr>
<tr>
<td>11</td>
<td>Great Tongue</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9</td>
</tr>
<tr>
<td>17</td>
<td>Hypopharynx</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9</td>
</tr>
<tr>
<td>82</td>
<td>Larynx Glottic</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9</td>
</tr>
<tr>
<td>86</td>
<td>Larynx Other</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9</td>
</tr>
<tr>
<td>84</td>
<td>Larynx Supraglottic</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9</td>
</tr>
<tr>
<td>23</td>
<td>Lip Lower</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9, 11</td>
</tr>
<tr>
<td>1</td>
<td>Lip Upper</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9, 11</td>
</tr>
<tr>
<td>16</td>
<td>Mouth Other</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9, 11</td>
</tr>
<tr>
<td>20</td>
<td>Nasopharynx</td>
<td>1, 25</td>
<td>1, 25</td>
<td>1, 1, 3, 4, 5, 6, 8, 9, 11</td>
</tr>
<tr>
<td>30</td>
<td>Oropharynx</td>
<td>1</td>
<td>1</td>
<td>1, 1, 3, 4, 5, 6, 8, 9, 10</td>
</tr>
<tr>
<td>21</td>
<td>Palatine</td>
<td>1</td>
<td>1</td>
<td>1, 1, 3, 4, 5, 6, 8, 9, 11</td>
</tr>
<tr>
<td>21</td>
<td>Palatine</td>
<td>1</td>
<td>1</td>
<td>1, 1, 3, 4, 5, 6, 8, 9, 10</td>
</tr>
<tr>
<td>36</td>
<td>Pharyngeal Esophagus</td>
<td>1, 25</td>
<td>1, 25</td>
<td>1, 1, 3, 4, 5, 6, 8, 9, 10</td>
</tr>
<tr>
<td>29</td>
<td>Pharynx Other</td>
<td>None</td>
<td>None</td>
<td>1, 1, 3, 4, 5, 6, 8, 9, 10</td>
</tr>
<tr>
<td>28</td>
<td>Salivary Gland Other</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9</td>
</tr>
<tr>
<td>28</td>
<td>Salivary Gland Other</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9</td>
</tr>
<tr>
<td>28</td>
<td>Salivary Gland Other</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9</td>
</tr>
<tr>
<td>9</td>
<td>Tongue Anterior</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9, 11</td>
</tr>
<tr>
<td>7</td>
<td>Tongue Base</td>
<td>1</td>
<td>1</td>
<td>3, 3, 4, 5, 6, 9, 10</td>
</tr>
</tbody>
</table>

### Site-Specific Factor 1

**Size of Involved Node - Note**

- **Required by FCDS & COC**
- **Code size of NODE, not size of metastasis**
- **Code largest diameter measured clinically or pathologically**
- **Code regional nodes only**
- **Size format same as tumor size with extra choices**
- **996 Described as less than 6 cm**
- **997 Described as more than 6 cm**
Treatment

Head and Neck Multidisciplinary Approach

- Treatment depends on:
  - Site
  - Location
  - Histology
  - Stage
  - Node Status

- Competence
- Convenience
- Cost
- Compliance
- Complications

*Head & Neck Cancer: A Multidisciplinary Approach, 2nd ed., pg 275*
Treatment Strategies

- **Surgery**
  - First choice when possible, but often limited by disfigurement and preservation of organ function such as speech and swallowing

- **Radiation**
  - Most head and neck cancer is sensitive to radiation while preserving organ function
    - Daily treatment lasts for 6-8 weeks
    - Side effects can be severe; permanent dry mouth, oral ulcers, osteoradionecrosis of the mandible, altered taste, weight loss, and tooth decay

- **Chemotherapy**
  - Can have dramatic response to treatment, but is often not a durable response
  - Side effects can also be severe; decreased blood counts, anemia, infections, weight loss, nausea, vomiting, and hair loss.
  - Newer targeted therapies have lower side effects

Treatment options for Head and Neck Cancer

<table>
<thead>
<tr>
<th>Disease Extent</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1N0-1 or T2 N0</td>
<td>Surgery or RT</td>
</tr>
<tr>
<td>T2N1 or T3-4 or N2-3</td>
<td>Combined modality</td>
</tr>
<tr>
<td>Recurrent or M1</td>
<td>Surgery and/or RT</td>
</tr>
<tr>
<td></td>
<td>Combined modality</td>
</tr>
<tr>
<td></td>
<td>Chemotherapy</td>
</tr>
<tr>
<td></td>
<td>Clinical Trials</td>
</tr>
</tbody>
</table>

- Early stages: Surgery or RT
- Advanced Stages: Chemo/RT or surgery followed by RT/ChemoRx
- Very Advanced: RT and Chemorx
### Common Treatment by Site

#### Oral Cavity
- **Lip**: R/S, R
- **Oral tongue**: S/R, R or S+R
- **Floor of mouth**: S/R, R or S+R
- **Gingiva**: S, S+R
- **Hard Palate**: S, S+R
- **Buccal mucosa**: S/R, S+R
- **Retromolar trigone**: S, S+R

#### Oropharynx
- **Soft palate**: R, R
- **Tonsillar fossa**: S/R, S+R
- **Ant. tonsillar pillar**: S/R, S+R
- **Pharyngeal tongue**: S/R, R
- **Pharyngeal wall**: R, S+R

#### Hypopharynx
- **Pyriform sinus**: S/R, R or S+R
- **Posterior pharynx**: R, R
Surgery

Lip

- Surgical removal of tissue
  - Moh’s procedure
- Frozen section and cutting using H&E
- Reconstructive surgery (reconstruct surgical defect)
- Chemo/Raduation if needed
- Rarely neck dissection

http://www.uwhealth.org/files/uwhealth/images/img/img_patients_mohs_method.gif
Surgery: Oral Cavity

Key:
X = complete
* = partial
o = optional

Tissues Removed

<table>
<thead>
<tr>
<th>Types of Surgery</th>
<th>Tumor Destruction</th>
<th>Tumor Only</th>
<th>Organ</th>
<th>Lymph Nodes</th>
<th>Other Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cryosurgery</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electrocautery (without specimen)</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laser surgery without specimen</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laser surgery with specimen</td>
<td>*/X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excisional biopsy</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Local surgical excision</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>examples: hemiglossectomy, tonsillectomy, alveolectomy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radical excision</td>
<td>X</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>examples: total glossectomy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Local or radical excision with</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>radical neck dissection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>examples: en bloc ressection,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>commando procedure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radical neck dissection only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Surgery of regional/distant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sites/nodes only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Salivary Gland Treatment Decisions

<table>
<thead>
<tr>
<th></th>
<th>T1, T2 Low grade</th>
<th>T1, T2 High grade</th>
<th>T3</th>
<th>T4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parotid gland</td>
<td>Complete resection</td>
<td>Resection Neck dissect.; RT if LN pos</td>
<td>Resection Neck dissect.; RT if LN pos</td>
<td>Resection Resection of other organs Neck if pos</td>
</tr>
<tr>
<td>Submandibular</td>
<td>Complete resection</td>
<td>Wide excision RT</td>
<td>Wide excision, nerves if pos RT</td>
<td>Excision of involved areas RT</td>
</tr>
</tbody>
</table>
Hypopharynx & Nasopharynx RX

- Surgery
- Combination Radiation & Chemotherapy
- Regular screening

Chemotherapy

Classical chemotherapy is directed at metabolic sites essential to cell replication
- Tumor cells replicate more frequently than normal cells
- However, standard chemotherapy does not specifically recognize cancer cells
- Highest morbidities in rapidly dividing cells: bone marrow, GI mucosa, and hair cells
Chemotherapy on H&N (MACH-NC) Results

Meta-Analysis of Chemotherapy on H&N MACH-NC Results

<table>
<thead>
<tr>
<th>Timing of Chemotherapy</th>
<th>Risk Reduction</th>
<th>P-value</th>
<th>Absolute Benefits (5yrs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjuvant</td>
<td>-6%</td>
<td>NS</td>
<td>-2%</td>
</tr>
<tr>
<td>Induction</td>
<td>4%</td>
<td>NS</td>
<td>2%</td>
</tr>
<tr>
<td>Concomitant</td>
<td>19%</td>
<td>&lt;0.00001</td>
<td>8%</td>
</tr>
<tr>
<td>Total</td>
<td>12%</td>
<td>&lt;0.00001</td>
<td>5%</td>
</tr>
</tbody>
</table>

NCCN: Lancet 2000; 355:949

Chemotherapy

- Single
- **Targeted Cetuximab** (Erbitux)
- Combinations
- NCCN Guidelines
- New Treatments

Targeted Chemotherapy: A specific receptor on the surface of common head and neck cancer cells is called Epidermal Growth Factor Receptor (EGFR)

- EGFR levels increase in in advanced stage tumors and in poorly differentiated tumors
- Cetuximab is an antibody against the EGFR receptor which can stop cell cycle progression and induce cell death.

http://www.azoncology.com/internet/
Types of Chemotherapy

**Single drugs**
- Bleomycin
- Camptosar (Ifosfamide)
- Carboplatin
- Cisplatin
- Docetaxel (Taxotere)
- 5FU
- Irinotecan
- Methotrexate
- Paclitaxel (Taxol)
- Vinorelbine (Navelbine)

**Combinations**
- 5FU/Cisplatin
- Docetaxel/Platinum
- Docetaxel/5FU
- Docetaxel/5FU/Platinum
- Erbitux (cetuximab) – combined with radiation – FDA approved February 2006


---

**Chemo-XRT**

Theoretical Benefits of Chemo-XRT

- Inhibiting repair of lethal and sublethal damage induced by radiotherapy
- Radiosensitizing hypoxic cells
- Reducing tumor burden, leading to an improved blood supply
- Redistributing tumor cells to a more radiosensitive cell cycle phase
- Inducing apoptosis
Radiation Therapy

- Standard Radiation
- Hyperfractionated, accelerated
- Intensity-Modulated Radiotherapy (IMRT)
- Brachytherapy - Not widely used for H&N cancers

IMRT Head & Neck

Intensity Modulated Radiation Therapy means that the intensity of the radiation beam in a given treatment field is varied via multiple multileaf blocking arrangements called segments.

- Intensity modulation combined with multiple fields (radiation beam angles) or arcs allows for conformal radiotherapy (i.e., high radiation isodose lines conform to the target volume and spare normal tissues).


http://www.azoncology.com/internet/
IMRT - Hypopharynx

http://www.azoncology.com/internet/

IGRT – Image Guided Radiation Therapy

- Daily X-rays or CT scans are performed and overlaid with the planning CT
- Millimeter adjustments are made with automatic couch position shifts
- Treatment becomes more accurate and consequently smaller target volumes will result in less side effects

http://www.azoncology.com/internet/
IGRT – MV X-rays

http://www.azoncology.com/internet/

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™)

Head and Neck Cancers

Version 2.2011

NCCN.org
NCCN Guidelines™ Version 1.2011
Head and Neck Cancers

PRINCIPLES OF SYSTEMIC THERAPY
The choice of chemotherapy should be individualized based on patient characteristics (performance status, goals of therapy).

Squamous Cell Cancers
Lip, Oral Cavity, Oropharynx, Hypopharynx, Glottic larynx, Supraglottic larynx, Ethmoid Sinus, Maxillary Sinus, Occult Primary:
Primary Systemic Therapy + concurrent RT
- Cisplatin alone (preferred) (category 1)
- Cetuximab (category 1)
- 5-Fluorouracil
- Cisplatin/paclitaxel
- Cisplatin/infusional 5-FU
- Carboplatin/infusional 5-FU
- Carboplatin/paclitaxel (category 2B)
Postoperative Chemoradiation
- Cisplatin alone (category 1 for high risk)
Induction*/Sequential chemotherapy
- Docetaxel/cisplatin/5-FU (category 1 if induction is chosen)
Following induction, agents to be used with concurrent chemoradiation typically include weekly platinums, weekly taxanes, or cetuximab.

Induction chemotherapy should only be done in a tertiary setting.

PRINCIPLES OF RADIATION THERAPY
Concurrent chemoradiation (preferred)
Conventional fractionation:
- Primary and gross adenopathy: ≥ 70 Gy (2.0 Gy/fraction)
- Neck
  - Uninvolved nodal stations: 44-64 Gy (1.6-2.0 Gy/fraction)
Chemoradiation
Based on published data, concurrent chemoradiation most commonly uses conventional fractionation at 2.0 Gy per fraction to ≥ 70 Gy in 7 wks with single agent cisplatin given every 3 weeks.
Other fraction sizes (eg, 1.8 Gy, conventional), multimagent chemotherapy, other dosing schedules of cisplatin; altered fractionation with chemotherapy are efficacious, and there is no consensus on the optimal approach.
Concurrent chemoradiation carries a high toxicity burden; altered fractionation or multimagent chemotherapy will likely further increase the toxicity burden. For any chemoradiation approach, close attention should be paid to published reports for the specific chemoradiation agent, dose, and schedule of administration. Chemoradiation should be performed by an experienced team and should include substantial supportive care.
PRINCIPLES OF RADIATION THERAPY

Concurrent chemoradiation (preferred)
Conventional fractionation:
- Primary and gross adenopathy: ≥ 70 Gy (2.0 Gy/fraction)
- Neck
  - Uninvolved nodal stations:
    - 44-64 Gy (1.6-2.0 Gy/fraction)

Chemoradiation
Based on published data, concurrent chemoradiation most commonly uses conventional fractionation at 2.0 Gy per fraction to ≥ 70 Gy in 7 weeks with single agent cisplatin given every 3 weeks at 100 mg/m² x 3 doses. Other fraction sizes (e.g., 1.8 Gy, conventional), multigent chemotherapy, other dosing schedules of cisplatin; altered fractionation with chemotherapy are efficacious, and there is no consensus on the optimal approach. In general, the use of concurrent chemoradiation carries a high toxicity burden; altered fractionation or multigent chemotherapy will likely further increase the toxicity burden. For any chemoradiation approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration. Chemoradiation should be performed by an experienced team and should include substantial supportive care.

PRINCIPLES OF SYSTEMIC THERAPY

The choice of chemotherapy should be individualized based on patient characteristics (performance status, goals of therapy).

**Nasopharynx**
- Chemoradiation followed by adjuvant chemotherapy
  - Cisplatin + RT followed by Cisplatin/5-FU (category 1)

**Recurrent, Unresectable or Metastatic (Incurable)**

**Combination therapy**
- Cisplatin or carboplatin + 5-FU + cetuximab (non-nasopharyngeal) (category 1)

**Single agent**
- Cisplatin
- Carboplatin
- Paclitaxel
- Docetaxel
- 5-FU
- Methotrexate

Note: These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
Clinical Trials

- Oral Cancer Adjuvant Therapy (OCAT) Trial – Phase III Mouth Neoplasms
- Erlotinib Prevention of Oral Cancer (EPOC)
- Excision Limits of Oral Cavity Tumor by Narrow Band Imaging
- TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
- Lyophilized Black Raspberries in Preventing Oral Cancer in High-Risk Patients Previously Diagnosed With Stage I-IV or In Situ Head and Neck Cancer
- Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
- Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (CTXMAB+RT)
- IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC

http://clinicaltrials.gov/search/open/condition=%22Mouth+Neoplasms%22

TEXT DOCUMENTATION

DEFENSIVE ABSTRACTING
CYA-Cover your abstract
Support all codes and dates with supplemental text - primary, histology, staging workup, Ext of Disease, First course of RX
Any Questions?

spence@med.miami.edu
mespino2@med.miami.edu

Happy Valentines

NEXT WEBCAST: To be announced